AbbVie (NYSE: ABBV) has extended an agreement with the University of Chicago related to collaborative preclinical oncology research. The North Chicago, Illinois–based company and the university are working together on research involving biomarkers and therapeutic applications related to existing AbbVie programs. In the past, the organizations have also explored new drug delivery methods to improve…
Lutathera supports improved survival for patients with neuroendocrine tumors
Novartis’ Lutathera, a drug indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, including foregut, midgut, and hindgut tumors, was recently highlighted at the World Congress on Gastrointestinal Cancer 2021. Dr. Jonathan R. Strosberg, head of the Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in…